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We analyzed the interactions between human primary cells from pancreatic ductal adenocarcinoma (PDAC) and
polymeric scaffolds to develop 3D cancer models useful for mimicking the biology of this tumor. Three scaffold types
based on two biocompatible polymeric formulations, such as poly(vinyl alcohol)/gelatin (PVA/G) mixture and poly
(ethylene oxide terephthalate)/poly(butylene terephthalate) (PEOT/PBT) copolymer, were obtained via different
techniques, namely, emulsion and freeze-drying, compression molding followed by salt leaching, and electrospinning.
In this way, primary PDAC cells interfaced with different pore topographies, such as sponge-like pores of different
shape and size or nanoﬁber interspaces. The aim of this study was to investigate the inﬂuence played by the scaffold
architecture over cancerous cell growth and function. In all scaffolds, primary PDAC cells showed good viability and
synthesized tumor-speciﬁc metalloproteinases (MMPs) such as MMP-2, and MMP-9. However, only sponge-like pores,
obtained via emulsion-based and salt leaching-based techniques allowed for an organized cellular aggregation very
similar to the native PDAC morphological structure. Differently, these cell clusters were not observed on PEOT/PBT
electrospun scaffolds. MMP-2 and MMP-9, as active enzymes, resulted to be increased in PVA/G and PEOT/PBT sponges,
respectively. These ﬁndings suggested that spongy scaffolds supported the generation of pancreatic tumor models
with enhanced aggressiveness. In conclusion, primary PDAC cells showed diverse behaviors while interacting with
different scaffold types that can be potentially exploited to create stage-speciﬁc pancreatic cancer models likely to
provide new knowledge on the modulation and drug susceptibility of MMPs.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a malignant
neoplasm, estimated to be the fourth cancer killer in the United
States and the eighth worldwide.1 Owing to PDAC minimal
symptoms leading to late-stage diagnoses, 75% of patients have
dismal prognosis with a 5-year survival rate of only 6%.1 The
remaining 25% of patients are those who undergo surgery for
localized diseases, but their 5-year survival rate barely reaches
20%.2 This malignancy has been associated with several clinical
factors responsible for such mortality rates: (i) lack of diagnostic
markers, (ii) high degree of infiltration and metastasis, and (iii)
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strong resistance to conventional chemotherapy. Early detection
of this disease thus seems to be the only means that would sub-
stantially impact patients’ long-term survival. However, it has
soon become evident that the accomplishment of this goal
requires an in-depth understanding of PDAC biology, which is
still a challenging subject of investigation.
The tumor is known to arise from the pancreatic duct system
and to show epithelial features, but the precise origin of PDAC
cells is still debated. Current data from genetically engineered
mouse models indicate that PDAC is likely to develop from a
metaplastic acinar-ductal cell.3 Progression from a non-tumor tis-
sue to infiltrating PDAC can start from different precursors,
namely, pancreatic intraepithelial neoplasia (PanIN), intraductal
papillary-mucinous neoplasm and cystic mucinous neoplasm.4
The best characterized PDAC derives from PanIN passing
through several stages up to the development of an in situ
tumor.5 Moreover, PDAC is able to attack the lymphatic system
and distant organs very early and quickly, thus becoming highly
metastatic even at the early stages.
In recent years, advances in cancer biology have highlighted
that tumor microenvironment (TME) plays a pivotal role on
cancer cell aggressiveness.6 Tumors can recruit TME-support-
ing cells by modifying the normal tissue environment, e.g.,
cancer-associated fibroblasts, which are involved in carcinogen-
esis stimulation,7,8 and tumor-associated macrophages, which
become altered during cancer development.9 Therefore, TME
must be considered a dynamic entity remodeling with the
tumor itself.
The TME of PDAC is particularly rich in stroma and very
heterogeneous, as it comprises cellular and extracellular matrix
(ECM) components.10 Several cell types concur to generate the
PDAC microenvironment, including fibroblasts, as well as pan-
creatic stellate, immune system, endothelial, cancer stem and
PDAC cells.11 To some extent, the failure of early PDAC diagno-
sis and the inefficiency of chemotherapy might be related to the
convolution of its TME.10 For complex tissue systems, like
tumors, the traditional bi-dimensional (2D) in vitro models have
revealed to be largely insufficient for drug screening and animal
models have shown poor predictability.12 Owing to the emerging
importance of TME in the comprehension of carcinogenesis
mechanisms, new biomimetic systems, such as 3-dimensional
(3D) in vitro models, are currently the object of study.13 It is a
fact that an evolution from 2D to 3D models has occurred in the
last decades.13 In the simplest 3D models, cancer cells are usually
agglomerated to form spheroids or embedded within biomaterial
gels (e.g., Matrigel, collagen).13 Only very recently has the tis-
sue engineering approach focused on cancer modeling, showing
the intriguing possibility of generating complex 3D models in
vitro.14,15 Indeed, some TME characteristics can be recreated in
advanced scaffold/cell systems.16,17 Moreover, physical-chemical
and mechanical phenomena regulating TME (e.g., cell-cell
forces, matrix stiffness), transport phenomena (e.g., mass and
energy transfer, fluid dynamics), and cellular kinetics (e.g.,
metabolism, signaling, proliferation) can be studied at the early
stages, leading to new insights into the tumor-regulating key
factors.18,19
In this study, we analyzed the interactions of primary PDAC
cells with 3 different polymeric scaffolds. The use of primary
cells, instead of immortalized cell lines, is of utmost importance
to create biomimetic tumor models in which cells and TME do
not show ab initio altered machinery.20 We selected 3 types of
scaffolds based on biocompatible polymeric formulations, such
as poly(vinyl alcohol)/gelatin (PVA/G) mixture and poly(ethyl-
ene oxide terephthalate)/poly(butylene terephthalate) (PEOT/
PBT) copolymer, manufactured with diverse architectures, such
as sponge-like structures and nanofiber meshes. These polymers
have been largely studied in tissue engineering applications and
have shown optimal biocompatibility.21,22 Since scaffold archi-
tecture and topography can play a key role in cell morphology
and differentiation, we chose these types of polymeric scaffolds
to assess a putatively different spatial arrangement of PDAC cells
in sponge-like pores versus nanofiber mesh interspaces. The anal-
yses on PDAC cell/scaffold constructs were aimed at assaying cell
viability and colonization, cell/material interactions, cell mor-
phology and supracellular organization. Finally, we investigated
the production of matrix metalloproteinases (MMPs) as key
enzymes involved in pancreatic cancer progression.23,24 Our
study reports on the effects of different scaffold types on human
primary PDAC cells, as a first step to develop tumor-biomimetic
3D in vitro models potentially usable for therapeutic screening.
Results and Discussion
This study was aimed at investigating the interactions between
human primary PDAC cells and polymeric scaffolds with differ-
ent design and composition to create biomimetic models of
PDAC. At such an early stage of scientific knowledge, it was
important to identify some promising scaffold candidates that
may steer further studies able to assess the role played by each
specific parameter systematically. This goal was pursued through
the accomplishment of 3 main objectives: (i) isolation of a pri-
mary PDAC cell line, (ii) fabrication of scaffolds with different
internal architectures, and (iii) investigation of cell morphology
and MMP-2 and MMP-9 expression after their culture within
the selected scaffolds.
To develop functional tissue units ex vivo, tissue engineering
has recently used strategies able to provide cells with the biomi-
metic cues of their original microenvironment, thus considering
the cells as interactive entities highly integrated with their native
niches.25 In scientific practice, it has also become evident that pri-
mary cells retain their origin-related information necessary for
biomimetic tissue development ex vivo. Indeed, immortalized
cell lines frequently show altered replicative potential and they
synthetize proteins at different levels and times if compared to
those of primary cells.20 To develop a tumor-biomimetic model,
such considerations should also apply to cancer cells. As an exam-
ple, we have reported that 3 commercial PDAC cell lines, all pos-
itive to Kirsten rat sarcoma viral oncogene homolog (K-ras)
mutation, showed different responses to Ukrain (a semi-synthetic
drug used to treat cancer) in terms of MMP-2 and MMP-9 pro-
duction.26 Cell lines are most easily accessible to researchers, but
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the use of primary cells isolated from tumor biopsies and charac-
terized for their mutations, would provide a more representative
TME and would therefore result in a model of increased reliabil-
ity. The first objective of our study was to isolate and characterize
primary human epithelial cells from PDAC explants (Fig. 1A).
In order to demonstrate that the isolated cells retained genetic
correspondence with the original tumor, we compared the puri-
fied cellular population in culture with the tumor cells obtained
via laser microdissection (Fig. 1B). Mutations of K-ras have been
found in almost 90% of PDACs.27 In this view, the mutational
status of K-ras gene can be considered as a fingerprint marker to
assess the pancreatic tumor origin of isolated cell lines. All the
commercial cell lines of pancreatic cancer show alteration in one
out of 3 codons often mutated in PDAC tissues. In our study, the
K-ras profile of the isolated cells showed a point gene mutation,
namely G216T codon 12 of exon 2 (Fig. 1C). This mutation
resulted to be identical to the one found in the cells microdissected
from the tumor tissue, thus confirming that our cell line actually
maintained the original hallmark of PDAC.
The second objective was to interface the primary cells with
different types of scaffolds to assess their preferential affinity
toward a specific architecture. A number of polymers and fabrica-
tion techniques have been used to produce 3D porous scaffolds
for tissue engineering.28 Conventional fabrication processes
include salt leaching, gas forming, phase separation and freeze-
drying to produce sponge-like matrices, or dry-, wet-, melt- and
electro-spinning techniques to produce fiber meshes. Both
spongy and fibrous scaffolds have been reported to support cell
growth and differentiation.29,30 However, the pore features of
the scaffolds have shown to affect proliferation, spatial organiza-
tion, differentiation and ECM production by cells, depending on
the cell type.28,29 Moreover, the cell function is directly influ-
enced by their interaction with the surrounding environment,
whether scaffold or native ECM. In line with these observations,
it is important to select scaffolds with a cell type-appropriate
architecture. We selected 3 different scaffold types that were pro-
duced via conventional scaffolding techniques. These methods
enable high surface to volume ratio,31 a parameter hypothesized
to favor epithelial-like cell colonization. We used PVA/G
sponge-like scaffolds produced via emulsion and freeze-drying,
PEOT/PBT sponge-like scaffolds produced via compression
molding and salt leaching, and PEOT/PBT fiber mesh scaffolds
produced via electrospinning. The architectural features of the
polymeric matrices were analyzed via scanning electron micros-
copy (SEM) (Fig. 2). PVA/G scaffolds appeared in the form of
soft and hydrophilic sponges. They showed highly intercon-
nected round-shaped pores with diameters ranging in 50-
300 mm (Fig. 2A1). The pore walls were about 5–10 mm thick
and had surfaces of diverse roughness (Fig. 2A2). PEOT/PBT
sponge-like scaffolds resulted to be rigid. They displayed suffi-
ciently interconnected cuboidal pores with diameters ranging in
300-500 mm (Fig. 2B1) that were surrounded by thick intrapo-
ral walls of about 80-200 mm and had smooth surfaces
(Fig. 2B2). Finally, PEOT/PBT fibrous scaffolds appeared like a
soft fabric of random fibers (Fig. 2C1), which showed a smooth
Figure 1. Isolation and characterization of the primary PDAC cell line
NFCR01. (A) Micrograph of a pure population of epithelial PDAC cells, as
obtained via contrast phase light microscopy (Original magniﬁcation
20£, scale bar D 50 mm). (B) Micrographs of laser microdissected epithe-
lial cells from a PDAC fresh tissue to perform DNA extraction (Original
magniﬁcation 10£). (C) K-ras gene mutation analysis of isolated cells
showing G216T mutation in codon 12 of exon 2.
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Figure 2. SEM micrographs of the produced scaffolds: (A) PVA/G sponge, (B) PEOT/PBT sponge, and (C) PEOT/PBT ﬁber mesh. Zoomed-out micrographs
highlight pore size and topography (A1–C1), while zoomed-in micrographs image pore surfaces (A2–C2).
Figure 3. SEM micrographs of PDAC cell/scaffold constructs: (A) PVA/G sponge, (B) PEOT/PBT sponge, and (C) PEOT/PBT ﬁber mesh. Zoomed-out micro-
graphs highlight interactions between cells and poral structures (A1–C1), while zoomed-in micrographs image single cells (A2–C2). Arrows indicate cells;
arrowheads indicate scaffold surfaces.
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surface and homogenous diameters of about 1 mm (Fig. 2C2).
Mesh thickness after collection was 220 § 56 mm.
The third objective concerned the evaluation of cell/scaffold
interactions. In the literature, only a few studies availing them-
selves of 3D models have been reported on pancreatic cancer.
Simple 3D models are based on cellular spheroids obtained from
PDAC cell lines. In these reports, tumor-derived cells have been
embedded in methylcellulose or gelatin-fibronectin gels.32,33 In a
tissue engineering study, an electrospun scaffold of poly(glyco-
lide-co-trimethylene carbonate)/G was used with pancreatic can-
cer stem cells.34 Finally, a fibrous scaffold based on
polyglyconate/G produced via electrospinning was tested with
cancer stem cells as a model for pancreatic metastasis.35 To our
knowledge, no extensive investigation using spongy scaffolds in
pancreas cancer modeling has been performed so far; instead,
only electrospun microfiber meshes have been used in the few
studies present in literature.33-35 For this preliminary scaffold
selection, 2 diverse polymeric sponges and an electrospun mesh
were chosen, the latter being used to align our study with the cur-
rent scientific background. Such scaffold types, cultured with
normal (i.e., non-cancerous) cells, including fibroblasts and
mesenchymal stem cells, resulted highly cytocompatible.36-38 In
this study, we investigated the interactions between these scaffold
and primary PDAC cells, in terms of cell morphology and scaf-
fold colonization. SEM analysis of cell/scaffold constructs, per-
formed both on the top surface and in cross sections, revealed
that pancreatic cells adhered on the inner surfaces of all the scaf-
fold types we used. In the PVA/G sponges, the inner pores were
well-colonized and the cells were extended across the pore walls
(Fig. 3A1) or layered on their surfaces (Fig. 3A1). Similarly, in
the PEOT/PBT sponges, the cells were well-stretched out on the
biomaterial surfaces covering large scaffold areas (Fig. 3B1).
Moreover, 3D cell placement with evidence of ECM molecule
extrusion could be documented (Fig. 3B2). Differently, in the
PEOT/PBT fibrous mesh, many cell protrusions were in contact
with the scaffold fibers (Fig. 3C1) which, in some cases, were
completely covered by cells (Fig. 3C2). Cell viability during cul-
ture was assessed using a metabolic test based on the alamarBlue
dye reduction percentage, which showed convergence of all the
scaffolds at the endpoint, being 47.5 § 3.5 %, 40.6 § 4.7 % and
45 § 1.4 % for PVA/G sponge, PEOT/PBT sponge and PEOT/
PBT fiber mesh, respectively, with no statistically significant dif-
ferences (P > 0.05) (Fig. 4A). The morphological and viability
outcomes were confirmed by histologic analysis. Hematoxylin and
eosin staining highlighted well-preserved cells with intact nuclei
and cytoplasm (Fig. 5A–C). In both the spongy scaffold types,
organized cell clusters showing a duct-like morphostructure could
be imaged and appeared to be very similar to those of the tumor
tissue (Fig. 5A, B, and D). Differently, these cellular structures
could not be found on PEOT/PBT fiber meshes (Fig. 5C1-3). Of
the 3 cell/scaffold constructs, the highest number of cell clusters
with ductal formation was detected in the PVA/G scaffolds
(Fig. 5A1-3). In our findings, PDAC cells are more likely to form
tumor-biomimetic 3D aggregates inside sponge-like pores, than
within nanofiber interspaces. Furthermore, the enhanced capabil-
ity of organized cluster formation in PVA/G sponges can depend
upon several factors, including chemical composition, pore size
and shape, roughness, as well as mechanical features of the scaffold
that deserve to be examined in future studies. It was also evident
that the different architecture of PEOT/PBT scaffolds affected
PDAC cell morphology.
Finally, we evaluated the MMP-2 and MMP-9 expression in
the cell/scaffold constructs via IHC and Western Blot. MMPs
are a family of proteases actively involved in ECM protein deg-
radation. These proteases are synthesized by cells as latent pro-
enzymes, which undergo activation by proteolytic cleavage of
the full length proteins. Owing to their capability of TME
remodeling via ECM disassembly, angiogenesis and inflamma-
tory cell recruitment, MMPs have been directly correlated with
Figure 4. (A) Bar graph showing alamarBlue reduction percentage in
PDAC cell/scaffold constructs along the culture time: PVA/G sponge,
PEOT/PBT sponge, and PEOT/PBT ﬁber mesh. Data are reported as mean
§ SD. Statistical analysis was performed at the endpoint (P > 0.05).
(B) Bar graph showing total protein contents in PDAC cell/scaffold
constructs at the culture endpoint. Data are reported as mean § SD;
asterisks indicate the following p values: * D 0.01; *** D 0.0001 and
**** D 0.00005.
Table 1. IHC analysis of MMP antigen intensity
PVA/G
sponge
PEOT/PBT
sponge
PEOT/PBT
ﬁber mesh Tumor
MMP-2 C/¡ CC C/¡ CCC
MMP-9 CCC CCCC CCCC CCCC
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cancer development and invasion,39 and indirectly with the
metastatic processes as enablers of epithelial-mesenchymal tran-
sition. The role of some MMPs, such as MMP-2, MMP-7 and
MMP-9, has been studied in PDAC.26,40 MMP-2 and MMP-9
are frequently investigated in PDAC molecular pathways
because of their connection with Smad4, which is a powerful
tumor-suppression protein downregulated in PDAC progres-
sion.27,40 It has been shown that K-ras gene mutation in con-
comitance with the loss of Smad4 mediates PDAC invasion
through an increased MMP-9 expression.27 Analysis of MMP
antigen intensity as obtained via immunohistochemistry (IHC)
is reported in Table 1. In our samples, IHC showed localized
intracellular positivity of MMP-2 (Fig. 5A2–D2), which was
most expressed in PEOT/PBT sponges (CC) (Fig. 5B2), fol-
lowed by PVA/G sponges (C/¡) and PEOT/PBT nanofibers
(C/¡) (Fig. 5A2 and C2), if compared to the intensity of
expression in the tumor tissue (CCC) (Fig. 5D2). MMP-9 was
intensely immunopositive in all 3 constructs (Fig. 5A3-D3).
Antigen intensity in both PEOT/PBT scaffolds was ubiquitous
and comparable to that of the tumor tissue (CCCC)
Figure 5. Light micrographs of histologic sections of PDAC cell/scaffold constructs (A–C) and tumor tissue (D): (A) PVA/G sponge, (B) PEOT/PBT sponge,
and (C) PEOT/PBT ﬁber mesh. (A1–D1) Hematoxylin and eosin (H&E) staining, showing cell morphology (original magniﬁcation 20£), IHC of (A2-D2)
MMP-2 and (A3–D3) MMP-9 (original magniﬁcations 40£). Arrows indicate organized clusters of cell with duct formation; “sc” indicates the scaffold
material. (E–G) Some controls of IHC reactions: (E and F) negative controls, i.e., omitting the primary antibody MMP-2, (G) positive control of MMP-2 per-
formed on a PDAC cell line. Scale bar D 50 mm.
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(Fig. 5B3-D3), while it appeared
slightly reduced (CCC) in PVA/G
scaffolds. Here, some cell clusters
appeared to be immunonegative
(Fig. 5A3). These aspects could rely
on different adaptations of the PDAC
cells to the polymeric substrates.
Bicinchoninic acid (BCA) assay per-
formed on cell lysates and normalized
by double-stranded (ds)-DNA con-
tent detected a diverse cellular synthe-
sis of proteins in the 3 cell/scaffold
constructs (Fig. 4B). The highest pro-
tein quantity produced per cell was
found in the PVA/G sponges (541.73
§ 203.69 mg/mg ds-DNA, p D
0.00005 and p D 0.0001 vs. PEOT/
PBT sponges and PEOT/PBT fiber
meshes, respectively). A less powerful
statistical difference (p D 0.01) was
also highlighted between the 2 types
of PEOT/PBT scaffolds, specifically,
the total protein amount per cell
resulted superior in the fiber meshes
(208.64 § 30.94 vs. 158.69 §
40.24 mg/mg ds-DNA). These data
indicate that a single PDAC cell was
averagely able to synthesize more pro-
teins in the PVA/G scaffolds than in
both PEOT/PBT scaffolds. Taken
together, the findings about protein
production per cell and the metabolic
activity of constructs suggest that
PVA/G sponges may be selective scaf-
folds for PDAC cells, possibly repre-
senting a model of enhanced PDAC
aggressiveness, with respect to both
PEOT/PBT scaffolds in which cells
displayed reduced synthesis activity.
Finally, Western Blot analysis
showed that cells grown on the differ-
ent scaffolds expressed high levels of
cleaved MMP-2 (the active enzyme),
while the full length MMP-2 (the proenzyme) was expressed at
low levels (Fig. 6A). Western Blot analysis also revealed a low
expression of full length MMP-9, while the active enzyme
was generally faintly detectable but in the PEOT/PBT sponge
(Fig. 6A). The volume intensity analysis of Western Blot
data was performed for the cleaved MMP-2 and full-length
MMP-9, as the other lanes were not sufficiently detected
(Fig. 6B). These quantitative results confirmed that the
cleaved MMP-2 was more intensely expressed than the full
length MMP-9 in all the constructs. The cleaved MMP-2 to
full-length MMP-9 ratio reached 4.90 in the PVA/G con-
structs, while it was 2.53 in both construct types based on
PEOT/PBT (both sponge and fiber mesh).
All in all, the obtained results indicated that the cleaved
MMP-2 was the most abundant enzyme in our samples. How-
ever, from a comparative standpoint, our outcomes
highlighted that both PEOT/PBT scaffold types stimulated
the PDAC cells to produce MMP-9, although this was mainly
detectable as a proenzyme, while PVA/G sponges best
enhanced the expression of cleaved MMP-2. In addition, only
the PEOT/PBT sponge was able to foster the cleaved MMP-9,
suggesting that scaffold architecture may affect the function of
primary PDAC cells. These slight variations of MMP levels
still need to be clearly elucidated and further confirmed using
primary PDAC cells from different patients. However, a dif-
ferential stimulation of MMPs by diverse scaffolds could be
Figure 6. (A) Western blot results show the expression of MMP-2 and MMP-9 proteins, both in the active
(cleaved) and inactive (full-length) forms in PVA/G sponge, PEOT/PBT sponge and PEOT/PBT ﬁber mesh.
Molecular weight (Mw) scales are reported on the left. Arrows indicate the bands of interest. (B) Bar
graph reporting the analysis of the band volume intensity for Western blot data (intensity£ 106) for the
3 cell/scaffold constructs.
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exploited to model a specific pathological status of clinical
interest.
Among the investigated scaffolds, PVA/G sponges greatly
favored primary PDAC cell organization in 3D clusters with
duct-like morphostructure, enhanced the proteic synthesis of cells
and in particular the production of active MMP-2. Therefore, it
seemed to be a suitable scaffold for developing a biomimetic
model of locally advanced PDAC. Moreover, PVA/G sponges
could be processed with routine protocols used in the hospitals,
appearing to be user-friendly models for cancer pathologists. On
the other hand, PEOT/PBT sponges allowed for organized cell
clustering with a large production of active MMP-2 and a
reduced but significant production of active MMP-9. Finally, in
the timeframe of our experiments, PEOT/PBT nanofiber meshes
did not enable the formation of tumor-like aggregates by PDAC
cells that synthetized active MMP-2 and inactive MMP-9. These
scaffolds are most likely to mimic PDAC evolution at a different
stage from that observed in the tumor biopsies. Owing to the
late-stage diagnosis of this tumor, current knowledge on the early
stages of PDAC evolution is still very limited. For these reasons,
the putative relevance of PEOT/PBT electrospun scaffolds in
PDAC modeling will deserve further discussion.
Materials and Methods
Ethical statement
The use of pancreas tumor tissue samples for research study
was approved by the Ethics Committee of the Azienda Ospeda-
liero-Universitaria Pisana (AOUP), Pisa, Italy (Approval #3909-
2013).
Isolation and culture of primary PDAC cells
PDAC pieces from surgery were washed extensively with
phosphate-buffered saline (PBS) and cut into approximately
1 mm3 fragments. These were plated onto 25 cm2 tissue culture
plastic flasks in RPMI-1640 medium (#F1255, Biochrom AG),
supplemented with 10% fetal bovine serum (#10500, Gibco),
2 mM L-glutamine (#G7513, Sigma-Aldrich), 100 mg/ml strep-
tomycin (#P0781, Sigma-Aldrich), 100 U/ml penicillin
(#P0781, Sigma-Aldrich) and 1 mg/ml type XI Collagenase (c-
9407, Sigma-Aldrich). The samples were cultured in a humidi-
fied incubator with 5% CO2.
41 After 18 h, the cells sprout out
from the explants were harvested and replated. The medium was
replaced every 3 days, until cell colonies were identified. The pri-
mary PDAC cell line used in this study is NFCR01.
Laser microdissection, nucleic acid extraction and mutation
analysis
Neoplastic cells were dissected from the tumor tissue using the
Leica LMD6000 instrument (Leica, Wetzlar, Germany), as
described in previous studies.41,42 Laser-captured cells were har-
vested in lysis buffer for DNA extraction. The mutation analysis
of the Kirsten rat sarcoma viral oncogene homolog (K-ras) was
performed in both the microdissected tumor tissue and the
tumor-derived primary cell culture to assess whether they
matched the pancreatic tumor origin. Samples were resuspended
in 20 mL of DNA extraction buffer, containing 0.005 M Tris-
HCl, 0.001 M EDTA, 1% Tween-20 and 0.1 mg/ml proteinase
K (pH 8.0), incubated overnight at 37C, and proteinase-K inac-
tivated at 95C for 10 min. The gene mutational status of the K-
ras coding exons (1-2) was determined by direct sequencing. Pri-
mers for polymer-chain reaction (PCR) were designed using the
Primer3 program (available at http://bioinfo.ut.ee/primer3/).
The annealing temperature used for PCR analysis was 57C. The
products were purified with the Montage PCR96 Cleanup Kit
(#P36316, Millipore); thereafter, 6 ml of purified samples were
sequenced using the BigDye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems). Sequencing was performed on an ABI
PRISM 3100 Genetic Analyzer (Applied Biosystems), as reported
in previous studies.43
Fabrication of PVA/G scaffolds
PVA/G scaffolds with 70/30 w/w composition ratio were
obtained via emulsion and freeze-drying.36 Briefly, an aqueous
solution of PVA (#341584, Sigma-Aldrich) and G (#G6650,
Sigma-Aldrich) was obtained at 50C under stirring and further
added with sodium lauryl sulfate to obtain a dense foam that was
quenched in liquid nitrogen and lyophilized. Dried foams were
stabilized by crosslinking with glutaraldehyde (GTA; #49630,
Sigma-Aldrich) vapors for 72 h, flushed under the flow cabinet
for 3 days, cut into cylinders (5 mm diameter, 3 mm thickness)
and subsequently treated with 2 M glycine (#410225, Sigma-
Aldrich) solution for 1 h to block GTA unreacted binding sites.
The resulting sponge is a highly porous, biocompatible, hydro-
philic and bio-stable material, suitable for tissue engineering
applications.36
Fabrication of PEOT/PBT scaffolds
PEOT/PBT copolymers were obtained from PolyVation B.V.,
The Netherlands. Sponge-like PEOT/PBT (300PEOT55PBT45)
scaffolds were prepared using a compression molding and parti-
cle-leaching method, as previously reported.37 A copolymer/salt
granule mixture was prepared with 400-600 mm granulometry
and a final salt volume percentage of 75%. The mixture was
heated to 180 C for 3 min followed by compression molding
for 1 min at 2.9 MPa inside a hot press (THB 008, Fontijne
Holland BV, The Netherlands), thus resulting in 120 £ 100 £
10 mm3 blocks. The salt was leached out by washing in demin-
eralized water for 48 h. Finally, the samples were dried under
reduced pressure in a vacuum oven and cut into cylinders
(5 mm diameter, 3 mm thickness) with a puncher.
An electrospinning apparatus was used to prepare PEOT/
PBT copolymer fiber meshes. A 20% w/v solution of
300PEOT55PBT45 was prepared in a solvent mixture of CHCl3
and HFIP (90/10% v/v), as previously reported.30 The solution
was introduced in a plastic syringe and placed on a syringe pump
(KDS 100, KD Scientific) to control polymer dispensing through
a spinneret. The following manufacturing parameters were cho-
sen: constant feed rate of 5 ml/h, a voltage of 15 kV and a dis-
tance between the spinneret and the collector of 15 cm. The
spinneret (21-gauge blunt tip) was positively charged and the
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collector was grounded. A rotating drum collector with rotational
velocity of 150 r.p.m. was used to produce and keep the mesh
thickness constant. Manufacturing was performed under con-
trolled environmental conditions (temperature of 25 § 1C and
30% humidity) and fiber collection time was 30 min.
After production, the PEOT/PBT scaffolds were treated with
argon (Ar) plasma to improve cell adhesion by changing surface
roughness.44 The scaffolds were placed inside a radio-frequency
glow-discharge chamber (Harrick Scientific Corp., NY, USA)
and a pre-vacuum was applied. Thereafter, Ar gas was flushed for
30 min under controlled 0.1–0.2 mbar vacuum with high set-
tings applied to the radio-frequency coil (740 V DC, 40 mA
DC, 29.6 W).
Culture of PDAC/scaffold constructs
The scaffolds (n D 5) were sterilized by overnight soaking in
absolute ethanol, washed 3 times with sterile 2£ Pen-Strep
(#P0781, Sigma-Aldrich)/Diflucan (Pfizer) saline and rinsed
with PBS prior to cell seeding. PDAC cells were seeded on the
scaffolds at a density of 1 £ 104 cells/mm3 of scaffold volume in
30 ml of culture medium, then the samples were placed for 1 h
in the incubator for cell adhesion. The specimens were fully cov-
ered with complete RMPI medium and cultured for 9 days pro-
viding media changes every 3 days.
Scanning electron microscopy (SEM)
SEM was used to analyze the architectural features of the plain
scaffolds and cell adhesion to the scaffold surfaces. Cellularized
samples underwent preliminary fixation (4% neutral buffered
formalin in PBS, overnight at 4C), dehydration in a graded
series of ethanol aqueous solutions up to anhydrous ethanol, dry-
ing by the critical point method (Balzers CPD030, Oerlikon
Balzers, Balzers, Liechtenstein), and cross-sectioning. Samples
were mounted on aluminum stumps, sputter-coated with gold
(Edwards Sputter Coater S150B, Edwards, NY, USA) and exam-
ined with a scanning electron microscope (JEOL JSM-5600 LV,
JEOL Ltd, Tokyo, Japan).
AlamarBlue assay
The viability of cell/scaffold constructs was investigated using
the alamarBlue assay (#BUF012A, Serotec Ltd). This bioassay
incorporates a REDOX indicator resulting in color change of the
culture medium according to cell metabolism. Owing to its negli-
gible toxicity, this assay can be performed multiple times on the
same samples. Samples and controls (including scaffolds with no
cells as blank controls), were incubated with the dye for 3 h
according to the manufacturer’s recommendations. Samples were
assayed at different culture time points 2, 5 and 8 days to assess
cell viability. After each assay, the supernatants were removed
from the cultures and replaced with fresh culture medium. The
samples were analyzed with a spectrophotometer (Victor3, Perki-
nElmer, Waltham, MA, USA) under a double wavelength read-
ing, 570 nm and 600 nm. Finally, dye reduction percentage was
calculated using dye molar extinction coefficients and appropriate
absorbance equations as provided by the manufacturer.
Total proteins and ds-DNA
Total protein and ds-DNA assays were carried out in cascade
on the same samples (n D 3) for value normalization. At the cul-
ture endpoint, the medium was removed from the constructs and
double distilled (dd)-water was added (2 ml/sample). These sam-
ples were frozen at ¡80C and stored. Plain PVA/G scaffold con-
trols were performed to subtract putatively scaffold-released from
cell-produced proteins. To enable both the proteins and the ds-
DNA to enter the solution, cell lysates were obtained performing
3 freeze/thaw cycles of the samples. Each cycle consisted of
10 min thawing at 37C in a sonicator bath (Bransonic 2510,
Bransonic, Danbury, CT, USA), followed by 10 min quenching
in liquid nitrogen. Ds-DNA content in cell lysates was measured
using the PicoGreen kit (Quant-iTTM, #P7589, Molecular Probes,
Invitrogen). The PicoGreen dye binds to ds-DNA and the result-
ing fluorescence intensity is directly proportional to ds-DNA con-
centration in solution. Standard solutions of DNA in dd-water at
concentrations ranging from 0–6 mg/ml were prepared and 50 ml
of standard or sample was loaded for quantification in a 96-well
black microplate. Working buffer and PicoGreen dye solution
were prepared according to the manufacturer’s instructions and
added at 100 and 150 ml per well, respectively. After a 10 min
incubation at room temperature in the dark, the fluorescence
intensity was measured on a plate reader (Victor3; PerkinElmer,
Waltham, MA) using an excitation wavelength of 485 nm and an
emission wavelength of 535 nm.
The total protein concentration was determined by the BCA
method (#23225, Pierce Biotechnology, Rockford, IL) following
the microplate procedure. Cell lysates and the working reagent
were loaded inside a 96-well microplate at 25 and 200 ml per
well, respectively. The microplate was incubated at 37C for
30 min. Samples were cooled down to room temperature and
absorbance was read at 562 nm on a plate reader (BioRad Labo-
ratories, Hercules, CA). Protein concentration of cellular speci-
mens was then obtained by reference to bovine serum albumin
(BSA) standards. Finally, total protein content was normalized
by DNA content as determined by the PicoGreen assay.
Histological analysis
For tumor characterization, 5 mm-thick frozen tissue sections
were thawed and fixed in 75% ethanol. The cell/scaffold con-
structs were treated for paraffin embedding. They were fixed in
4% neutral buffered formalin overnight at 4C and washed in
1£ PBS. Constructs of PDAC cells and PVA/G sponges could
be processed using routine protocols for surgical pathology speci-
mens. Other scaffolds required modified procedures for histo-
logic processing, as reported hereafter. Constructs based on
PEOT/PBT sponges were dehydrated with a graded series of eth-
anol aqueous solutions for extended times (4 h each step), up to
absolute ethanol (30 h). The specimens were clarified in xylene
at 58C for 2 h. Constructs based on PEOT/PBT fiber meshes
were dehydrated with a graded series of ethanol aqueous solutions
up to absolute ethanol (6 h) and clarified in xylene at 40C for
90 min. All samples were then soaked in liquid paraffin at 60C
for 2 h and paraffin-embedded. A standard microtome allowed
8 mm-thick sections to be obtained that were mounted on slides
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and dried at 37C. Samples were then rehydrated using xylene
and ethanol solutions. Finally, sections of tumor tissue and cell/
scaffold constructs were stained with hematoxylin and eosin for
morphologic analysis.
Immunohistochemistry (IHC)
The protein expression of both MMP-2 and MMP-9 was
examined by IHC in the tumor models and in the tumor tissue,
the latter as a positive control. Formalin-fixed sections were
hydrated. Antigen retrieval was performed through soaking
3 times for 3 minutes in 10 mM citrate buffer pH 6 at 96C.
The sections were treated for endogenous peroxidase quenching,
by incubating the specimens in a 3% H2O2 solution at room
temperature in the dark for 15 min. Samples were incubated
with monoclonal mouse anti-human MMP-2 or MMP-9 anti-
bodies (#4022 and #3852, respectively, CST Cell Signaling,
Inc.) at 1:100 dilution for 1 h and stained with avidin-biotin-
peroxidase complex (Revealing Kit #951D-22 and DAB substrate
Kit #957D-22, Cell Marque). The sections were counterstained
with hematoxilyn. Negative controls for both the cell/scaffold
constructs and the tumor were obtained by replacement of the
primary antibody with buffer. Antigen positivity was scored
according to the following criteria: ¡ D negative; C D weakly
positive; CC D positive; CCC D strongly positive; CCCC D
very strongly positive.
Western Blot
The MMP-2 and MMP-9 expression was evaluated by West-
ern Blot analysis at the end point. Briefly, cell/scaffold constructs
were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 2 mM EDTA, 1% NP-40) added with antipro-
teases 1£ (#S8830, Sigma-Aldrich). The samples were main-
tained in ice for 1 h and vortexed every 10 min for mechanical
disruption. Protein concentration was determined using the BCA
microplate method (#23225, Thermo Fisher). Equal quantities
of proteins (20 mg/sample) were separated on a 4–15% poly-
acrylamide gel (#4561083, BioRad) under reducing conditions,
and then transferred to a nitrocellulose membrane (#1704158,
Trans Turbo Blot system, BioRad). The membranes were
blocked with 4% dry fat milk in 0.1% TBS Tween (T-TBS) and
incubated with either rabbit polyclonal anti MMP-2 or anti
MMP-9 (#4022 and #3852, respectively, CST Cell Signaling,
Inc.) diluted in 5% bovine serum albumin (BSA) in T-TBS, at
concentrations of 1:1000 and 1:500, respectively, at 4C over-
night. An anti-rabbit horseradish peroxidase (HRP)-conjugated
antibody (#074-1506, KPL), diluted 1:2000 in 5% BSA in T-
TBS, at room temperature for 1 h was used as secondary anti-
body and immunocomplexes were detected by chemilumines-
cence (#170-5061, ECL clarity, BioRad) using Chemi-Doc
XRSC (BioRad). The data were analyzed using Image Lab soft-
ware (BioRad).
Statistical analysis
Statistical significance in quantitative analyses was evaluated
using the 2-tailed t test for either paired (alamarBlue assay) or
unpaired (Total Protein assay) data, followed by Bonferroni’s
correction. The data underwent both descriptive, i.e., mean §
standard deviation (SD), and inferential statistics (p-values).
Conclusion
In this study, we investigated the interactions of primary
PDAC cells with 3 different polymeric scaffolds, based on bio-
compatible polymers (PVA/G mixture and PEOT/PBT copoly-
mer) and manufactured so as to have different inner
architectures. Analyses showed that PDAC cells were viable
inside the 3 scaffolds after a 9-day culture and that they synthe-
sized tumor-specific MMPs, such as MMP-2 and MMP-9. Inter-
estingly, independently of the polymer formulation, sponge-like
pores (50–500 mm diameter) allowed cellular clustering similar
to the native cancer morphostructure. However, the highest
number of PDAC clusters with early ductal formations were
observed in the PVA/G scaffolds. These findings demonstrate
that pore size and topography, as well as polymer chemistry, can
affect the spatial organization of PDAC cells ex vivo; further-
more, poral structures originated from nanofiber interspaces pre-
vented clustered formations by PDAC cells. In our samples, the
cleaved MMP-2 was the most abundantly produced enzyme.
However, some slight differences could be highlighted. In PVA/
G sponges the active MMP-2 enzyme resulted to be higher to the
detriment of inactive MMP-9 than the ones detected in the other
scaffolds. On the other hand, PEOT/PBT sponges stimulated
some production of active MMP-9 together with active MMP-2.
Instead, the cells inside PEOT/PBT nanofibers mainly synthe-
sized inactive MMP-9 and slightly reduced MMP-2. This indi-
cates that the PVA/G and PEOT/PBT spongy constructs could
mimic pancreatic tumor models at locally advanced stages. In
conclusion, PDAC cells showed diverse behavior when interact-
ing with different scaffold types that can be exploited to model
various phases of pancreatic tumor development and invasion.
The availability of advanced 3D in vitro models of PDAC could
be employed in the near future to screen drug susceptibility and
MMP modulation, according to specific interactions with the
pancreatic TME.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
The Italian Association for Cancer Research (AIRC) is
acknowledged for contributing to this study. The authors thank
Dr. Randa Ishak (Dept. of Civil and Industrial Engineering, Uni-
versity of Pisa, Italy) for her SEM technical support.
Funding
This research was funded by the Italian Ministry of University
and Research (MIUR) (PRIN #2009FZZ4XM), Istituto Toscano
Tumori (ITT) (approval number 6204-2012).
e955386-10 Volume 4 Issue 1Biomatter
References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics,
2012. CA Cancer J Clin 2012; 62:10-29;
PMID:22237781; http://dx.doi.org/10.3322/caac.20138
2. Vincent A, Herman J, Schulick R, Hruban RH, Gog-
gins M. Pancreatic cancer. Lancet 2011; 378:607-20;
PMID:21620466; http://dx.doi.org/10.1016/S0140-
6736(10)62307-0
3. Esposito I, Konukiewitz B, Schlitter AM, Kl€oppel G.
New insights into the origin of pancreatic cancer: role
of atypical flat lesions in pancreatic carcinogenesis.
Pathologe 2012; 33:189-93; PMID:23011021; http://
dx.doi.org/10.1007/s00292-012-1673-x
4. Maitra A, Hruban RH. Pancreatic cancer. Annu
Rev Pathol 2008; 3:157-88; PMID:18039136; http://
dx.doi.org/10.1146/annurev.pathmechdis.3.121806.
154305
5. Herreros-Villanueva M, Gironella M, Castells A, Bujanda
L. Molecular markers in pancreatic cancer diagnosis. Clin
Chim Acta 2013;418:22-9; PMID:23305796; http://dx.
doi.org/10.1016/j.cca.2012.12.025
6. Quail DF, Joyce JA. Microenvironmental regulation of
tumor progression and metastasis. Nat Med 2013;
19:1423-37; PMID:24202395; http://dx.doi.org/
10.1038/nm.3394
7. Olumi, AF, Olumi AF, Grossfeld GD, Hayward SW,
Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associ-
ated fibroblasts direct tumor progression of initi-ated
human prostatic epithelium. Cancer Res 1999;
59:5002-11; PMID:10519415
8. Dumont N, Dumont N, Liu B, Defilippis RA, Chang
H, Rabban JT, Karnezis AN, Tjoe JA, Marx J, Parvin
B, et al. Breast fibroblasts modulate early dissemina-
tion, tumorigenesis, and metastasis through. Neoplasia
2013; 15:249-62; PMID:23479504
9. Qian BZ, Pollard JW. Macrophage diversity enhances
tumor progression and metastasis. Cell 2010; 141:39-
51; PMID:20371344; http://dx.doi.org/10.1016/j.
cell.2010.03.014
10. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N,
Tuveson DA. Pancreas Cancer Microenvironment Clin
Cancer Res 2012; 18:4266-76.
11. Iovanna J, Mallmann MC, Gonc¸alves A, Turrini O,
Dagorn JC. Current knowledge on pancreatic cancer.
Front Oncol 2012; 31:2-6.
12. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical
predictive value of the in vitro cell line, human xeno-
graft, and mouse allograft preclinical cancer models.
Clin Cancer Res 2003; 9:4227-39; PMID:14519650
13. Kim JB. Three-dimensional tissue culture models in
cancer biology. Semin Cancer Biol 2005; 15:365-
77; PMID:15975824; http://dx.doi.org/10.1016/j.
semcancer.2005.05.002
14. Hutmacher DW, Horch RE, Loessner D, Rizzi S, Sieh
S, Reichert JC, Clements JA, Beier JP, Arkudas A, Blei-
ziffer O, et al. Translating tissue engineering technol-
ogy platforms into cancer research. J Cell Mol Med
2009; 13(8A):1417-27; PMID:19627398; http://dx.
doi.org/10.1111/j.1582-4934.2009.00853.x
15. Ghajar CM, Bissell MJ. Tumor engineering: the other
face of tissue engineering. Tissue Eng Part A 2010;
16:2153-6; PMID:20214448; http://dx.doi.org/10.1089/
ten.tea.2010.0135
16. Burdett E, Kasper FK, Mikos AG, Ludwig JA.
Engineering tumors: a tissue engineering perspective
in cancer biology. Tissue Eng Part B Rev
2010;6:351-9; PMID:20092396; http://dx.doi.org/
10.1089/ten.teb.2009.0676
17. Ricci C, Moroni L, Danti S. Cancer tissue engineering:
new perspectives in understanding the biology of solid
tumors. A critical review. OA Tissue Eng 2013; 1:4;
http://dx.doi.org/10.13172/2052-9643-1-1-607
18. DelNero P, Song YH, Fischbach C. Microengineered
tumor models: insights & opportunities from a physical
sciences-oncology perspective. Biomed Microdevices
2013; 15:583-93; PMID:23559404; http://dx.doi.org/
10.1007/s10544-013-9763-y
19. Hutmacher DW, Loessner D, Rizzi S, Kaplan DL,
Mooney DJ, Clements JA. Can tissue engineering con-
cepts advance tumor biology research? Trends Biotech-
nol 2010; 28(3):125-33; PMID:20056286; http://dx.
doi.org/10.1016/j.tibtech.2009.12.001
20. Czekanska EM, Stoddart MJ, Ralphs JR, Richards
RG, Hayes JS. A phenotypic comparison of osteo-
blast cell lines versus human primary osteoblasts for
biomaterials testing. J Biomed Mater Res A 2013;
102:2636-43; PMID:23983015; http://dx.doi.org/
10.1002/jbm.a.34937
21. DeMerlis CC, Schoneker DR. Review of the oral toxic-
ity of polyvinyl alcohol (PVA). Food Chem Toxicol
2003; 41:319-26; PMID:12504164; http://dx.doi.org/
10.1016/S0278-6915(02)00258-2
22. Bartha L, Hamann D, Pieper J, Peters F, Riesle J, Vajda
A, Novak PK, Hangody LR, Vasarhelyi G, Bodo L,
et al. A clinical feasibility study to evaluate the safety
and efficacy of PEOT/PBT implants for human donor
site filling during mosaicplasty. Eur J Orthop Surg
Traumatol 2013; 23:81-91; PMID:23412412; http://
dx.doi.org/10.1007/s00590-011-0907-6
23. Singh N, Das P, Datta Gupta S, Sahni P, Pandey RM,
Gupta S, Chauhan SS, Saraya A. Prognostic signifi-
cance of extracellular matrix degrading enzymes-cathep-
sin L and matrix metalloproteases-2 [MMP-2] in
human pancreatic cancer. Cancer Invest 2013; 31:
461-71.
24. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A,
Boeck W, Wagner M, Wilda M, Friess H, B€uchler M,
et al. Role of MT-MMPs and MMP-2 in pancreatic can-
cer progression. Int J Cancer 2000; 85:14-20;
PMID:10585576; http://dx.doi.org/10.1002/(SICI)1097-
0215(20000101)85:1<14::AID-IJC3>3.0.CO;2-O
25. Ingber DE,MowVC, Butler D, Niklason L, Huard J,Mao
J, Yannas I, Kaplan D, Vunjak-Novakovic G. Tissue engi-
neering and developmental biology: going biomimetic. Tis-
sue Eng 2006; 12:3265-83; PMID:17518669; http://dx.
doi.org/10.1089/ten.2006.12.3265
26. Funel N, Costa F, Pettinari L, Taddeo A, Sala A, Chir-
iva-Internati M, Cobos E, Colombo G, Milzani A,
Campani D, et al. Ukrain affects pancreas cancer cell
phenotype in vitro by targeting MMP-9 and intra-/
extracellular SPARC expression. Pancreatology 2010;
10:545-52; PMID:20975318; http://dx.doi.org/
10.1159/000266127
27. Bera A, Zhao S, Cao L, Chiao PJ, Freeman JW. Onco-
genic K-Ras and loss of Smad4 mediate invasion by
activating an EGFR/NF-kB axis that induces expres-
sion of MMP9 and uPA in human pancreas progenitor
cells. PLoS One 2013; 8:e82282; PMID:24340014;
http://dx.doi.org/10.1371/journal.pone.0082282
28. Loh QL, Choong C. Three-dimensional scaffolds for tissue
engineering applications: role of porosity and pore size. Tis-
sue Eng Part B Rev 2013; 19:485-502; PMID:23672709;
http://dx.doi.org/10.1089/ten.teb.2012.0437
29. Mallick KK, Cox SC. Biomaterial scaffolds for tissue
engineering. Front Biosci (Elite Ed) 2013; 5:341-60;
PMID:23276994
30. Ingavle GC, Leach JK. Advancements in electrospin-
ning of polymeric nanofibrous scaffolds for tissue engi-
neering. Tissue Eng Part B Rev 2014; 20(4):277-93.
31. Hutmacher DW. Scaffold design and fabrication tech-
nologies for engineering tissues–state of the art and
future perspectives. J Biomater Sci Polym Ed 2001;
12:107-24; PMID:11334185; http://dx.doi.org/
10.1163/156856201744489
32. Longati P, Jia X, Eimer J, Wagman A, Witt MR,
Rehnmark S, Verbeke C, Toftgǻrd R, Lohr M,
Heuchel RL. 3D pancreatic carcinoma spheroids
induce a matrix-rich, chemoresistant phenotype
offering a better model for drug testing. BMC
Cancer 2013; 13:95; PMID:23446043; http://dx.
doi.org/10.1186/1471-2407-13-95
33. Hosoya H, Kadowaki K, Matsusaki M, Cabral H,
Nishihara H, Ijichi H, Koike K, Kataoka K, Miyazono
K, Akashi M, et al. Engineering fibrotic tissue in pan-
creatic cancer: a novel three-dimensional model to
investigate nanoparticle delivery. Biochem Biophys Res
Comm 2012; 419:32-7; PMID:22321398; http://dx.
doi.org/10.1016/j.bbrc.2012.01.117
34. He Q, Wang X, Zhang X, Han H, Han B, Xu J, Tang K,
Fu Z, Yin H. A Tissue engineered subcutaneous pancreatic
cancer model for antitumor drug evaluation. Int J Nanome-
dicine 2013; 8:1167-76; PMID:23658483; http://dx.doi.
org/10.2147/IJN.S42464
35. Wang X, Zhang X, Fu Z, Yin H. A bioengineered
metastatic pancreatic tumor model for mechanistic
investigation of chemotherapeutic drugs. J Biotech-
nol 2013; 166:166-73; PMID:23747489; http://dx.
doi.org/10.1016/j.jbiotec.2013.05.008
36. Moscato S, Mattii L, D’Alessandro D, Cascone MG,
Lazzeri L, Serino LP, Dolfi A, Bernardini N. Interac-
tion of human gingival fibroblasts with PVA/gelatine
sponges. Micron 2008; 39:569-79; PMID:17702585;
http://dx.doi.org/10.1016/j.micron.2007.06.016
37. Du C, Klasens P, Haan RE, Bezemer J, Cui FZ, de
Groot K, Layrolle P. Biomimetic calcium phosphate
coatings on Polyactive 1000/70/30. J Biomed Mater
Res 2002; 59:535-46; PMID:11774312; http://dx.doi.
org/10.1002/jbm.1267
38. Moroni L, Licht R, de Boer J, de Wijn JR, van Blitters-
wijk CA. Fiber diameter and texture of electrospun
PEOT/PBT scaffolds influence human mesenchymal
stem cell proliferation and morphology, and the release
of incorporated compounds. Biomaterials 2006;
27:4911-22; PMID:16762409; http://dx.doi.org/
10.1016/j.biomaterials.2006.05.027
39. Coussens LM, Fingleton B, Matrisian LM. Matrix met-
alloproteinase inhibitors and cancer: trials and tribula-
tions. Science 2002; 295:2387-92; PMID:11923519;
http://dx.doi.org/10.1126/science.1067100
40. Wiercinska E, Naber HP, Pardali E, van der Pluijm
G, van Dam H, ten Dijke P. The TGF-b/Smad
pathway induces breast cancer cell invasion through
the up-regulation of matrix metalloproteinase 2 and
9 in a spheroid invasion model system. Breast Can-
cer Res Treat 2011; 128:657-66; PMID:20821046;
http://dx.doi.org/10.1007/s10549-010-1147-x
41. Funel N, Giovannetti E, Del Chiaro M, Mey V,
Pollina LE, Nannizzi S, Boggi U, Ricciardi S, Del
Tacca M, Bevilacqua G, et al. Laser microdissection
and primary cell cultures improve pharmacogenetic
analysis in pancreatic adenocarcinoma. Lab Invest
2008; 88:773-84; PMID:18490900; http://dx.doi.
org/10.1038/labinvest.2008.40
42. Giovannetti E, van der Velde A, Funel N, Vasile E, Per-
rone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina
LE, et al. High-throughput microRNA (miRNAs)
arrays unravel the prognostic role of MiR-211 in pan-
creatic cancer. PLoS One 2012; 7:e49145;
PMID:23155457; http://dx.doi.org/10.1371/journal.
pone.0049145
43. Funel N, Morelli M, Giovannetti E, Del Chiaro M,
Pollina LE, Mosca F, Boggi U, Cavazzana A, Campani
D. Loss of heterozygosity status of D9S105 marker is
associated with downregulation of Kr€uppel-like factor
4 expression in pancreatic ductal adenocarcinoma and
pancreatic intraepithelial lesions. Pancreatology 2011;
11:30-42; PMID:21412023; http://dx.doi.org/
10.1159/000322990
44. Woodfield TB, Miot S, Martin I, van Blitterswijk CA,
Riesle J. The regulation of expanded human nasal
chondrocyte re-differentiation capacity by substrate
composition and gas plasma surface modification. Bio-
materials 2006; 27:1043-53; PMID:16125219; http://
dx.doi.org/10.1016/j.biomaterials.2005.07.032
www.landesbioscience.com e955386-11Biomatter
